Satranidazole with Ofloxacin
Satranidazole is a nitroimidazole derivative with antibacterial and antiprotozoal properties. Ofloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase, leading to disruption of DNA replication and ultimately bacterial cell death. The combination of Satranidazole with Ofloxacin provides a broad-spectrum antimicrobial effect against various bacterial and protozoal infections.This combination is indicated for the treatment of mixed infections, including respiratory tract infections, urinary tract infections, gastrointestinal infections, gynecological infections, skin and soft tissue infections, and sexually transmitted infections.
The dosage should be determined by the healthcare provider based on the specific infection and patient characteristics. It is essential to follow the prescribed regimen and complete the entire course of treatment.
This combination is contraindicated in patients with a history of hypersensitivity to nitroimidazole derivatives, fluoroquinolones, or any other component of the formulation. It is also contraindicated in pregnant women and breastfeeding mothers.
-Caution is advised in patients with a history of seizures, as fluoroquinolones may increase the risk of seizures. -Patients with a history of tendon disorders should be monitored closely for potential tendonitis or tendon rupture. -Avoid concurrent administration with antacids containing aluminum or magnesium, as they may interfere with the absorption of Ofloxacin.
Common side effects may include nausea, vomiting, diarrhea, headache, dizziness, and rash. Serious but rare side effects may include allergic reactions, peripheral neuropathy, and tendon disorders.
-Avoid concurrent use with other drugs that may prolong the QT interval. -Warfarin may interact with Ofloxacin, leading to an increased risk of bleeding. -Theophylline levels may be elevated when used concurrently with Ofloxacin.
